Noticias de ATHE_US
Noticias del mercado
Últimas noticias sobre ATHE_US — 106 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.
Alterity Therapeutics Limited - Depositary Receipt (ATHE) price target increased by 15.37% to 4.93
Alterity Therapeutics Limited - Depositary Receipt (ATHE) price target increased by 15.37% to 4.93
Alterity Therapeutics Files May 2026 Form 6-K, Releases New Corporate Presentation
[6-K] ALTERITY THERAPEUTICS LTD Current Report (Foreign Issuer) | ATHE SEC Filing - Form 6-K
ATHE Alterity releases quarterly earnings with no revenue or EPS data disclosed; investors await more details. - Market Buzz Alerts
Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy
MRI scan tracks brain iron to distinguish MSA from Parkinson’s
MELBOURNE, Australia y SAN FRANCISCO, 7 de mayo de 2026 (GLOBE NEWSWIRE) – Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (
MELBOURNE, Australia y SAN FRANCISCO, 7 de mayo de 2026 (GLOBE NEWSWIRE) – Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (
MELBOURNE, Australia y SAN FRANCISCO, 7 de mayo de 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” o “la Compañía”), una empresa de biotecnología dedicada al desarrollo de tratamientos modificadores de enfermedades neurodegenerativas, anunció hoy que las presentaciones relacionadas con el programa de desarrollo de la compañía en atrofia sistémica múltiple (MSA) se realizarán en múltiples conferencias médicas en mayo. 2026. Sociedad Internacional de Resonancia Magnética en Medicina 202
Alterity Therapeutics Limited - Depositary Receipt (ATHE) price target decreased by 35.66% to 4.27
Página 1 de 6
